Related Experiment Video
Updated: Jun 5, 2026
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
Endostar, a modified recombinant human endostatin, exhibits synergistic effects with dexamethasone on angiogenesis
Xing-Qi Li1, Bo-Yang Shang, Dong-Chun Wang
1Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Abstract:
We evaluated the efficacy of a combination strategy, Endostar, a modified recombinant human endostatin, plus dexamethasone, against angiogenesis and hepatoma growth. By colony formation assay, synergistic effects of the combination of Endostar and dexamethasone were observed on the proliferations of human umbilical endothelial cells and hepatoma Bel-7402 cells. Endostar plus dexamethasone inhibited angiogenesis events in vitro. Examined with transwell assay, HUVECs invasion was more efficiently suppressed by combination of Endostar and dexamethasone than by the respective single drug. But the combination treatment of Endostar and dexamethasone to Bel-7402 cells did not alter the migration of HUVECs. The migration of HUVEC tended to coincident with VEGF secretion as determined by ELISA. Tube formation assay, rat aortic ring assay and chick embryo chorioallantoic membrane (CAM) assay indicated that the anti-angiogenesis effects of Endostar were significantly enhanced by dexamethasone. In mouse hepatoma H22 and human hepatoma Bel-7402 subcutaneous xenograft, Endostar plus dexamethasone presented more potent efficacy in tumor growth suppression than the single drug treatments. The above confirms the synergism of Endostar and dexamethasone on anti-angiogenesis and suppression of hepatoma growth. The potentiation effects of the combination indicate that Endostar plus dexamethasone might be a positive strategy for cancer therapy.
Insights
The combination of Endostar and dexamethasone synergistically inhibits angiogenesis and hepatoma growth. This potent anti-cancer strategy shows enhanced efficacy compared to single treatments, offering a promising approach for cancer therapy.
Area of Science:
- Oncology
- Angiogenesis Research
- Pharmacology
Background:
- Hepatocellular carcinoma (HCC) remains a significant health concern with limited effective treatments.
- Angiogenesis is crucial for tumor growth and metastasis.
- Endostar (modified recombinant human endostatin) and dexamethasone are potential anti-cancer agents.
Purpose of the Study:
- To evaluate the combined efficacy of Endostar and dexamethasone against angiogenesis and hepatoma growth.
- To investigate the synergistic effects of this combination therapy.
Main Methods:
- Colony formation assay to assess cell proliferation.
- Transwell assay to evaluate cell invasion.
- ELISA to measure VEGF secretion.
- Tube formation assay, rat aortic ring assay, and CAM assay for anti-angiogenesis.
- In vivo studies using mouse hepatoma H22 and human hepatoma Bel-7402 xenografts.
Main Results:
- The combination of Endostar and dexamethasone demonstrated synergistic effects on human umbilical endothelial cells and hepatoma Bel-7402 cell proliferation.
- Combined treatment significantly inhibited in vitro angiogenesis and HUVEC invasion.
- Dexamethasone significantly enhanced the anti-angiogenesis effects of Endostar.
- The combination therapy showed more potent tumor growth suppression in vivo than single treatments.
Conclusions:
- Endostar and dexamethasone exhibit synergistic anti-angiogenic and anti-hepatoma growth properties.
- This combination strategy presents a potent therapeutic approach for cancer treatment.
- The enhanced efficacy suggests a promising role for Endostar plus dexamethasone in clinical cancer therapy.
